logo
Plus   Neg
Share
Email

AbbVie Initiates Phase 3 Trial For HUMIRA

AbbVie Inc. (ABBV), a research-based biopharmaceutical company, Thursday said it has initiated a Phase 3 clinical trial to test the use of HUMIRA as a treatment of fingernail psoriasis in patients with moderate to severe chronic plaque psoriasis.

The multinational, double-blind, placebo-controlled study is for a period of 26 weeks and is expected to enroll 200 patients with moderate to severe chronic plaque psoriasis with fingernail psoriasis. The primary endpoints for the trial will be evaluated after 26 weeks and are based on advice received from regulatory agencies

Psoriasis is a non-contagious, chronic immune disease that speeds the growth cycle of skin cells and results in thick, scaly areas of skin. Psoriasis also affects the fingernails, causing pitting, discoloration, loosening and irregular contour of the fingernail, according to National Institute for Arthritis and Musculoskeletal and Skin Diseases.

For comments and feedback contact: editorial@rttnews.com

Follow RTT
>